Efforts to promote breastfeeding as the best option for infants may have led some parents to believe formula is not a good option and to turn to the Internet to find someone else’s milk, a practice the FDA says is unsafe.
Almost no independent research has investigated the potential health impacts of long-term feminine hygiene product use. Studies have generally taken place through product manufacturers—who aren’t required to release the results in full to the public.
It’s been two years since the FDA made certain types of emergency contraception available without a prescription to women of all ages, but Indian Health Service has yet to update its policy.
Liletta, an IUD just approved by the FDA, is being marketed in the United States through a unique partnership between manufacturers who hope to bring the device to more people at a lower cost. However, it is still unclear whether those savings will be felt by all women.
A New York grand jury failed to indict the officers involved in Eric Garner’s death, while the Roberts Court heard arguments in two big cases for equality advocates.
This week, six lab-grown penises are almost ready for implantation, and an Italian couple apparently became stuck together after a tryst at the beach went awry.
If not enough women and people of color are included in clinical trials, it is not possible to determine how they’re affected by the new drug or device. And without this information women, particularly women of color, can’t make informed decisions about the medical products available.
Recently, social media lit up with the news that Amazon.com vendors are selling Plan B One-Step emergency contraception for as low as $16.90 plus shipping. We have to ask: How is that possible?
Though the FDA decision to permit generic EC pill manufacturers to sell their products over the counter represents a gain for those with the most access to resources, ultimately the decision reflects pharmaceutical manufacturing companies’ interests, rather than the lives of those most adversely affected by lack of access to EC.
Current recommendations suggest Pap tests be used as primary screening tools for cervical cancer, but some experts would like to see newer DNA testing used more often.